- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 498/18 - Bridged systems
Patent holdings for IPC class C07D 498/18
Total number of patents in this class: 816
10-year publication summary
|
45
|
57
|
43
|
67
|
69
|
68
|
75
|
76
|
69
|
32
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2036 |
35 |
| Revolution Medicines, Inc. | 233 |
24 |
| Pfizer Inc. | 3374 |
19 |
| ImmunoGen, Inc. | 399 |
19 |
| Regeneron Pharmaceuticals, Inc. | 4252 |
17 |
| Novartis AG | 10856 |
16 |
| Janssen Pharmaceutica N.V. | 3392 |
16 |
| Bristol-myers Squibb Company | 4875 |
12 |
| Bayer Pharma AG | 1061 |
12 |
| Abbott Laboratories | 2403 |
11 |
| Polyphor AG | 87 |
11 |
| Turning Point Therapeutics, Inc. | 100 |
11 |
| Vertex Pharmaceuticals Incorporated | 1599 |
10 |
| Bayer AG | 3332 |
9 |
| Dana-Farber Cancer Institute, Inc. | 2562 |
9 |
| Shenzhen TargetRx, Inc. | 142 |
9 |
| Aeovian Pharmaceuticals, Inc. | 19 |
9 |
| The Regents of the University of California | 19887 |
8 |
| Biosensors International Group, Ltd. | 38 |
8 |
| Oncodesign S.A. | 15 |
8 |
| Other owners | 543 |